Trials / Completed
CompletedNCT06287073
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 299 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JARDIANCE® | JARDIANCE® |
Timeline
- Start date
- 2024-03-29
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
- First posted
- 2024-02-29
- Last updated
- 2026-01-30
Locations
12 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06287073. Inclusion in this directory is not an endorsement.